Drugs / ABT-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03246854 | Jul 2017 → Aug 2018 | head and neck cancer, non-small cell lung carcinoma | National Health Research Institutes, Taiwan | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05532696 | Sep 2022 → Nov 2026 expected | non-small cell lung carcinoma | Anbogen Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05532696 ↗ |
| Known as | DBPR112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03246854 ↗ |
| Route | Oral | “by oral administration” NCT05532696 ↗ |